Understanding adjuvant endocrine therapy persistence in breast Cancer survivors.

ABSTRACT:

Background

Adjuvant endocrine therapy (AET) significantly decreases the risk of breast cancer recurrence and mortality. Notwithstanding the demonstrated efficacy of AET, 31-73% of breast cancer survivors do not persist with AET. The purpose of this study was to explore breast cancer survivors' experiences and perspectives of persisting with AET and to identify the psychosocial and healthcare system factors that influence AET persistence.

Methods

Informed by interpretive descriptive methodology and relational autonomy theory, individual interviews were conducted with 22 women diagnosed with early-stage breast cancer who had been prescribed AET. These participants also completed a demographic form and a survey that assessed their perceived risk of recurrence. Interviews were a

SUBMITTER: Lambert LK 

PROVIDER: S-EPMC6042363 | biostudies-literature | 2018 Jul

REPOSITORIES: biostudies-literature